ARTICLE | Finance

Ebb & Flow

April 2, 2001 7:00 AM UTC

For years the industry has struggled to put a valuation on early stage research.

Banc of America analyst Jim Reddoch provided a series of benchmarks he uses to value genomics and post-genomics companies, as well as a view of how he sees the new tools penetrating the R&D process over the next 15 years, at the 2001 Banc of America Securities Healthcare Conference in Las Vegas last week...